Takhzyro denied as not FDA-approved for this use by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for takhzyro are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why a "Not FDA-Approved" Denial for Takhzyro Is Almost Certainly an Error

Takhzyro (lanadelumab) holds full FDA approval for its indicated use in hereditary angioedema. A denial citing lack of FDA approval is almost always an administrative or coding error — the claim may have been submitted under a diagnosis code that does not match the approved indication, or the plan's system has an outdated formulary or policy entry.

This denial is highly likely to be overturned on appeal. FDA approval is documented public record, and an insurer cannot classify an approved, on-label use as unapproved.

## Federal Appeal Rights

• ACA §2719 / ERISA §503 give you the right to internal appeal and independent external review.
• Internal appeal deadline: 180 days from the denial notice.
• External review window: approximately 4 months after final internal denial.
• Expedited review (72-hour turnaround) is available — laryngeal HAE attacks are potentially fatal, making urgency easy to document.

## Appeal Timeline

1. Obtain the denial letter and the exact policy language UHC applied. 2. Pull the current FDA prescribing information from DailyMed (dailymed.nlm.nih.gov) — this is your primary exhibit. 3. Verify the diagnosis code submitted on the claim matches the FDA-approved indication; correct and resubmit if miscoded (this may resolve the denial without a formal appeal). 4. If resubmission fails, file a formal internal appeal with the FDA label attached. 5. Escalate to external IRO if denied internally.

## Documentation to Gather

• FDA prescribing label: Current full prescribing information from DailyMed, clearly showing the approved indication.
• Diagnosis confirmation: Lab or genetic documentation of HAE matching the approved indication.
• Claim diagnosis code: Confirm with your provider that the ICD-10 code submitted matches the approved indication (e.g., D84.1 for HAE).
• Prescriber attestation: Letter stating that Takhzyro is being used for its FDA-approved indication, not off-label.
• Policy language: The exact UHC policy definition of "not FDA-approved" — compare it against the FDA approval record.

## Criteria-Mapping Structure

| Denial Basis | Rebuttal Evidence | |---|---| | Drug not FDA-approved | DailyMed label showing approval date and indication | | Use is off-label | Prescriber letter confirming on-label use; ICD-10 code alignment | | No recognized clinical evidence | Applicable professional society guidelines (e.g., relevant allergy/immunology or HAE association guidance) |

This type of denial resolves most readily at the internal appeal stage. Attach the FDA label directly to your appeal letter and request that UHC's medical director review the approval record before a final determination.